18F-Fluorodeoxyglucose PET in Locally Advanced Non-small Cell Lung Cancer: From Predicting Outcomes to Guiding Therapy.

This article summarizes advancements in using FDG-PET for patients with locally advanced NSCLC treated with definitive radiation therapy (RT). This article discusses prognostication of outcome based on pretreatment or midtreatment PET metrics, using textural image features to predict treatment outcomes, and using PET to define RT target volumes and inform RT dose modifications. The role of PET is evolving and is moving toward using quantitative image information, with the overarching goal of individualizing therapy to improve outcomes for patients with NSCLC. PMID: 31735302 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: PET Clin Source Type: research

Related Links:

Publication date: Available online 10 December 2019Source: Respiratory Medicine Case ReportsAuthor(s): Keima Ito, Tetsuya Oguri, Norihisa Takeda, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Tomoko Tajiri, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Akio NiimiAbstractA 76-year-old man was admitted to our hospital with cough and dyspnea. He was diagnosed with advanced lung cancer. Nivolumab was given as second-line treatment, cytotoxic chemotherapy was given as third-line treatment, and nivolumab re-challenge was given as fourth-line treatment. Thereafter, 41 chemotherapy courses were administered o...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Authors: Liao Y, Wang X, Zhong P, Yin G, Fan X, Huang C Abstract As a malignant tumor with poor prognosis, accurate and effective treatment of non-small cell lung cancer (NSCLC) is crucial. To predict overall survival in patients with stage II and III NSCLC, a nomogram was constructed using data from the Surveillance, Epidemiology and End Results database. Eligible patients with NSCLC with available clinical information diagnosed between January 1, 2010 and November 31, 2015 were selected from the database, and the data were randomly divided into a training set and a validation set. Univariate and multivariate Cox ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Abstract BACKGROUND AND PURPOSE: To analyze outcomes of non-small cell lung cancer (NSCLC) patients with brain metastases harboring EGFR or ALK mutations and examine for differences between tyrosine kinase inhibitors (TKIs) alone, radiotherapy (RT) alone (either whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS)), or combined TKIs and RT. MATERIALS AND METHODS: Thirty studies were identified. PATIENTS: with brain metastases from NSCLC. INTERVENTION: initial TKIs alone with optional salvage RT, RT alone, or TKIs and RT. CONTROL: wild-type NSCLC and TKIs alone for mutational ...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
118 patients with stage IIB-IV non-small cell lung cancer were treated with isotoxically-escalated concurrent chemoradiotherapy, to median prescribed doses of 64.5 and 67.6 Gy in 30 fractions over 5 (N=36) or 6 weeks (N=82). Toxicity was acceptable for both schedules. Overall survival was longer in 6-week than 5-week patients (median 41.2 versus 22.1 months; HR=0.56, 95%CI: 0.32-0.98, p=0.04). Progression-free survival was also longer in 6-week patients (median 21.1 versus 8.0 months; HR=0.53, 95%CI: 0.33-0.86, p=0.01).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
This article reviews the current indications and future directions of radiotherapy in lung cancer management. PMID: 31739938 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Hematol Oncol Clin North Am Source Type: research
Objective: Anti-PD-1 antibodies can cause drug-induced pneumonitis. We aimed to identify the clinical and radiologic characteristics, the incidence, risk factors, and appropriate management of pneumonitis related to anti-PD-1 immunotherapy in patients with non-small cell lung cancer (NSCLC).Materials and Methods: Medical records and chest computed tomography scans of patients with NSCLC treated with anti-PD-1 antibodies between January 2016 and June 2018 at the Kanagawa Cancer Center were retrospectively analyzed. Clinical characteristics of patients treated with anti-PD-1 antibodies who developed pneumonitis were compared...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusion: For elderly NSCLC with stage IV disease, radical local treatment might significantly benefit survival in certain subgroups. Further well-designed studies are highly warranted to confirm these findings.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
We present a prospective study of hypofractionated, image-guided radiation therapy (HIGRT) to a single site of metastatic disease concurrently with atezolizumab in patients with metastatic NSCLC.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
This article summarizes advancements in using FDG-PET for patients with locally advanced NSCLC treated with definitive radiation therapy (RT). This article discusses prognostication of outcome based on pretreatment or midtreatment PET metrics, using textural image features to predict treatment outcomes, and using PET to define RT target volumes and inform RT dose modifications. The role of PET is evolving and is moving toward using quantitative image information, with the overarching goal of individualizing therapy to improve outcomes for patients with NSCLC.
Source: PET Clinics - Category: Radiology Authors: Source Type: research
ConclusionRadiomics analysis based on planning CT images allowed a  classifier and predictive models capable of identifying patients at risk of nodal relapse and high-risk of bad prognosis to be built. The radiomics signatures identified were mostly related to tumor heterogeneity.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Radiation Therapy